Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results

OBJECTIVES: Adjuvant chemotherapy decision in patients with hormone receptor positive, HER2 negative breast cancer (BC) is challenging. Ki-67 is widely used for adjuvant therapy decision in BC. The multigene assay EndoPredict (EP) has shown to provide valid and additional information about the risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Noske, Aurelia, Anders, Sophie-Isabelle, Ettl, Johannes, Hapfelmeier, Alexander, Steiger, Katja, Specht, Katja, Weichert, Wilko, Kiechle, Marion, Klein, Evelyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375593/
https://www.ncbi.nlm.nih.gov/pubmed/31786414
http://dx.doi.org/10.1016/j.breast.2019.11.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375593/
https://www.ncbi.nlm.nih.gov/pubmed/31786414
http://dx.doi.org/10.1016/j.breast.2019.11.004

Ejemplares similares